009290 — Kwangdong Pharmaceutical Co Balance Sheet
0.000.00%
- KR₩261bn
- KR₩356bn
- KR₩2tn
- 56
- 90
- 54
- 79
Annual balance sheet for Kwangdong Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 112,019 | 149,273 | 187,701 | 208,632 | 206,181 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 236,137 | 226,039 | 241,486 | 227,311 | 262,402 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 525,963 | 584,494 | 587,818 | 605,747 | 665,424 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 137,815 | 124,679 | 138,013 | 153,532 | 212,432 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 792,776 | 830,643 | 883,845 | 932,024 | 1,078,065 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 308,362 | 302,187 | 325,495 | 353,567 | 456,810 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 369,815 | 352,982 | 384,668 | 414,693 | 533,449 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 422,961 | 477,661 | 499,177 | 517,331 | 544,616 |
Total Liabilities & Shareholders' Equity | 792,776 | 830,643 | 883,845 | 932,024 | 1,078,065 |
Total Common Shares Outstanding |